Article PDF
References
Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM . Epidemiologic aspects of uveal melanoma [review]. Surv Ophthalmol 1988;32:239–51.
Fidler IF . Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990;50:6130–8.
Moretti S, Martini E, Berti E, Pinzi C, Gianotti B . Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res 1993;3:235–9.
Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD, editors. Molecular biology of the cell. 3rd ed. New York: Garland Publishing, 1994:995–9.
Kramer RH, Vu M, Cheng YF, et al. Integrin expression in malignant melanoma. Cancer Metastasis Rev 1991;10:49–59.
Mortarini R, Anchini A . From adhesion to signalling: roles of integrins in the biology of human melanoma. Melanoma Res 1993;3:87–9.
Hart IA, Birch M, Marshall JF . Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 1991;10:115–28.
Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumour progression. Cancer Res 1990;50:6757–64.
Kramer RH, McDonald KA, Vu MP . Human melanoma cells express a novel integrin receptor for laminin. J Biol Chem 1989;264:15642–9.
Cheresh DA . Structure, function, and biological properties of integrin αvβ3 on human melanoma cells. Cancer Metastasis Rev 1991;10:3–10.
ten Berge PJ, Danen EH, van Muijen GN, Jager MJ, Ruiter DJ . Integrin expression in uveal melanoma differs from cutaneous melanoma. Invest Ophthalmol Vis Sci 1993;34:3635–40.
Creyghton WM, de Waard-Sledinga I, Danen EHJ, Luyten GPM, van Muijen GNP, Jager MJ . Cytokinemediated modulation of integrin, ICAM-1 and CD44 expression on human uveal melanoma cells in vitro. Melanoma Res 1995;5:235–42.
Rohrbach JM, Wild M, Riedinger C, Kreissig I, Thiel HJ . Premetastatic uveal melanoma cells do not express laminin receptors. German J Ophthalmol 1994;3:144–7.
MacNeil S, Wagner M, Kirkham EA, Blankson MS, Lennard MS, Goodall T, et al. Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res 1993;3:67–74.
MacNeil S, Wagner M, Rennie IG . Tamoxifen inhibition of ocular melanoma cell attachment to matrix proteins. Pigment Cell Res 1994;7:222–6.
MacNeil S, Wagner M, Rennie IG . Investigation of the role of signal transduction in attachment of ocular melanoma cells to matrix proteins: inhibition of attachment by calmodulin antagonists including tamoxifen. Clin Exp Metastasis 1994;12:375–84.
Tomlinson S, MacNeil S, Walker SW, Ollis CA, Merritt JE, Brown BL . Calmodulin and cell function. Clin Sci 1984;66:497–508.
Fierro MT, Bertero M, Novelli M, Appino A, Doveil GC, Colonna S, et al. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993;3:127–31.
Buckley MT, Goa KL . Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1989;37:451–90.
Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992;327:516–23.
Lam H-YP . Tamoxifen is a calmodulin antagonist in the action of cAMP phosphodiesterase. Biochem Biophys Res Commun 1984;118:27–32.
Lopes MCF, Value MGP, Carvalho AP . Ca2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res 1990;50:2753–8.
Brian CAO, Liskamp RM, Soloman DH, Weinstein IB . Inhibition of protein kinase C by tamoxifen. Cancer Res 1985;45:2462–5.
Goodall T, Buffey JA, Rennie IG, Benson M, Parsons MA, Faulkner MK, et al. Effect of melanocyte stimulating hormone on human cultured choroidal melanocytes. uveal melanoma cells, and retinal epithelial cells. Invest Ophthalmol Vis Sci 1994;35:826–37.
MacNeil S, Wagner M, Wowk I, et al. Intracellular regulation of cell adhesion to extracellular matrix components in murine B16 melanoma cells of differing metastatic potential. Melanoma Res 1992;2:345–54.
Cottam DW, Rees RC . Regulation of matrix metallo-proteinases: their role in tumor invasion and metastasis. Int J Oncol 1993;2:861–72.
Alizadeh H, Ding M, Berman M, Bellinham D, Comerford SA, Gething MH, et al. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 1995;13:449–58.
Ossowski L, Russo-Payne H, Wilson EL . Inhibition of urokinase-type plasminogen activator by antibody: the effect on dissemination of a human tumour in the nude mouse. Cancer Res 1991;51:274–81.
Hearing VJ, Law LW, Carti A, Appella E, Blasi F . Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988;48:1270–8.
Meissauer A, Kramer MD, Hofman M, Erkell LJ, Jacob E, Schirrmacher V, et al. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp Cell Res 1991;192:453–9.
Cottam DW, Rennie IG, Woods K, Parsons MA, Bunning RA, Rees RC . Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Invest Ophthalmol Vis Sci 1992;33:1923–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rennie, I. Uveal melanoma: Tumour phenotype and metastatic potential. Eye 11, 239–242 (1997). https://doi.org/10.1038/eye.1997.58
Issue Date:
DOI: https://doi.org/10.1038/eye.1997.58